Pancreaticoduodenectomy

Does it have a role in the palliation of pancreatic cancer?

Keith D. Lillemoe, John L. Cameron, Charles J. Yeo, Taylor A. Sohn, Attila Nakeeb, Patricia K. Sauter, Ralph H. Hruban, Ross A. Abrams, Henry A. Pitt

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Objective: The authors define the role of palliative pancreaticoduodenectomy in patients with pancreatic carcinoma. Background: Decreases in perioperative morbidity and modality and improved long term survival associated with pancreaticoduodenectomy for patients with pancreatic carcinoma have clearly established a role for this operation when performed with curative intent. However, most surgeons remain hesitant to perform pancreaticoduodenectomy unless surgical margins are widely clear, choosing rather to perform palliative biliary and gastric bypass. Methods: A single- institution retrospective review was performed comparing the outcome of 64 consecutive patients undergoing pancreaticoduodenectomy for pancreatic carcinoma with gross or microscopic evidence of adenocarcinoma at the surgical resection margins, and 62 consecutive patients found to be unresectable at the time of laparotomy because of local invasion without evidence of metastatic disease (stage III). Combined biliary and gastric bypass were performed in 87% of patients not resected. Results: The two groups were similar with respect to age, gender, race, and presenting symptoms. The hospital modality rate was identical in both groups (1.6%). Fifty-eight percent of patients undergoing pancreaticoduodenectomy had an uncomplicated postoperative course compared with 68% of patients undergoing palliative bypass (not significant). The length of postoperative hospital stay after pancreaticoduodenectomy was 18.4 days, which was significantly longer (p <005) than for patients undergoing palliative bypass (150 days). The overall actuarial survival (Kaplan-Meier) was improved significantly in patients undergoing pancreaticoduodenectomy (p <0.02). Postoperative chemotherapy and radiation therapy improved survival in both groups. Conclusions: Pancreaticoduodenectomy can be performed with a similar perioperative morbidity and modality and only a minimal increase in hospital stay when compared with traditional surgical palliation. Pancreaticoduodenectomy with postoperative chemotherapy and radiation therapy is associated with improved long-term survival when compared with patients treated with surgical bypass. These data support the role of palliative pancreaticoduodenectomy in patients with pancreatic carcinoma and with local residual disease.

Original languageEnglish (US)
Pages (from-to)718-728
Number of pages11
JournalAnnals of Surgery
Volume223
Issue number6
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Pancreaticoduodenectomy
Pancreatic Neoplasms
Gastric Bypass
Survival
Length of Stay
Radiotherapy
Morbidity
Drug Therapy
Laparotomy
Adenocarcinoma

ASJC Scopus subject areas

  • Surgery

Cite this

Lillemoe, K. D., Cameron, J. L., Yeo, C. J., Sohn, T. A., Nakeeb, A., Sauter, P. K., ... Pitt, H. A. (1996). Pancreaticoduodenectomy: Does it have a role in the palliation of pancreatic cancer? Annals of Surgery, 223(6), 718-728. https://doi.org/10.1097/00000658-199606000-00010

Pancreaticoduodenectomy : Does it have a role in the palliation of pancreatic cancer? / Lillemoe, Keith D.; Cameron, John L.; Yeo, Charles J.; Sohn, Taylor A.; Nakeeb, Attila; Sauter, Patricia K.; Hruban, Ralph H.; Abrams, Ross A.; Pitt, Henry A.

In: Annals of Surgery, Vol. 223, No. 6, 1996, p. 718-728.

Research output: Contribution to journalArticle

Lillemoe, KD, Cameron, JL, Yeo, CJ, Sohn, TA, Nakeeb, A, Sauter, PK, Hruban, RH, Abrams, RA & Pitt, HA 1996, 'Pancreaticoduodenectomy: Does it have a role in the palliation of pancreatic cancer?', Annals of Surgery, vol. 223, no. 6, pp. 718-728. https://doi.org/10.1097/00000658-199606000-00010
Lillemoe, Keith D. ; Cameron, John L. ; Yeo, Charles J. ; Sohn, Taylor A. ; Nakeeb, Attila ; Sauter, Patricia K. ; Hruban, Ralph H. ; Abrams, Ross A. ; Pitt, Henry A. / Pancreaticoduodenectomy : Does it have a role in the palliation of pancreatic cancer?. In: Annals of Surgery. 1996 ; Vol. 223, No. 6. pp. 718-728.
@article{3c4dcb25185a4d7eb46292f0c3885484,
title = "Pancreaticoduodenectomy: Does it have a role in the palliation of pancreatic cancer?",
abstract = "Objective: The authors define the role of palliative pancreaticoduodenectomy in patients with pancreatic carcinoma. Background: Decreases in perioperative morbidity and modality and improved long term survival associated with pancreaticoduodenectomy for patients with pancreatic carcinoma have clearly established a role for this operation when performed with curative intent. However, most surgeons remain hesitant to perform pancreaticoduodenectomy unless surgical margins are widely clear, choosing rather to perform palliative biliary and gastric bypass. Methods: A single- institution retrospective review was performed comparing the outcome of 64 consecutive patients undergoing pancreaticoduodenectomy for pancreatic carcinoma with gross or microscopic evidence of adenocarcinoma at the surgical resection margins, and 62 consecutive patients found to be unresectable at the time of laparotomy because of local invasion without evidence of metastatic disease (stage III). Combined biliary and gastric bypass were performed in 87{\%} of patients not resected. Results: The two groups were similar with respect to age, gender, race, and presenting symptoms. The hospital modality rate was identical in both groups (1.6{\%}). Fifty-eight percent of patients undergoing pancreaticoduodenectomy had an uncomplicated postoperative course compared with 68{\%} of patients undergoing palliative bypass (not significant). The length of postoperative hospital stay after pancreaticoduodenectomy was 18.4 days, which was significantly longer (p <005) than for patients undergoing palliative bypass (150 days). The overall actuarial survival (Kaplan-Meier) was improved significantly in patients undergoing pancreaticoduodenectomy (p <0.02). Postoperative chemotherapy and radiation therapy improved survival in both groups. Conclusions: Pancreaticoduodenectomy can be performed with a similar perioperative morbidity and modality and only a minimal increase in hospital stay when compared with traditional surgical palliation. Pancreaticoduodenectomy with postoperative chemotherapy and radiation therapy is associated with improved long-term survival when compared with patients treated with surgical bypass. These data support the role of palliative pancreaticoduodenectomy in patients with pancreatic carcinoma and with local residual disease.",
author = "Lillemoe, {Keith D.} and Cameron, {John L.} and Yeo, {Charles J.} and Sohn, {Taylor A.} and Attila Nakeeb and Sauter, {Patricia K.} and Hruban, {Ralph H.} and Abrams, {Ross A.} and Pitt, {Henry A.}",
year = "1996",
doi = "10.1097/00000658-199606000-00010",
language = "English (US)",
volume = "223",
pages = "718--728",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Pancreaticoduodenectomy

T2 - Does it have a role in the palliation of pancreatic cancer?

AU - Lillemoe, Keith D.

AU - Cameron, John L.

AU - Yeo, Charles J.

AU - Sohn, Taylor A.

AU - Nakeeb, Attila

AU - Sauter, Patricia K.

AU - Hruban, Ralph H.

AU - Abrams, Ross A.

AU - Pitt, Henry A.

PY - 1996

Y1 - 1996

N2 - Objective: The authors define the role of palliative pancreaticoduodenectomy in patients with pancreatic carcinoma. Background: Decreases in perioperative morbidity and modality and improved long term survival associated with pancreaticoduodenectomy for patients with pancreatic carcinoma have clearly established a role for this operation when performed with curative intent. However, most surgeons remain hesitant to perform pancreaticoduodenectomy unless surgical margins are widely clear, choosing rather to perform palliative biliary and gastric bypass. Methods: A single- institution retrospective review was performed comparing the outcome of 64 consecutive patients undergoing pancreaticoduodenectomy for pancreatic carcinoma with gross or microscopic evidence of adenocarcinoma at the surgical resection margins, and 62 consecutive patients found to be unresectable at the time of laparotomy because of local invasion without evidence of metastatic disease (stage III). Combined biliary and gastric bypass were performed in 87% of patients not resected. Results: The two groups were similar with respect to age, gender, race, and presenting symptoms. The hospital modality rate was identical in both groups (1.6%). Fifty-eight percent of patients undergoing pancreaticoduodenectomy had an uncomplicated postoperative course compared with 68% of patients undergoing palliative bypass (not significant). The length of postoperative hospital stay after pancreaticoduodenectomy was 18.4 days, which was significantly longer (p <005) than for patients undergoing palliative bypass (150 days). The overall actuarial survival (Kaplan-Meier) was improved significantly in patients undergoing pancreaticoduodenectomy (p <0.02). Postoperative chemotherapy and radiation therapy improved survival in both groups. Conclusions: Pancreaticoduodenectomy can be performed with a similar perioperative morbidity and modality and only a minimal increase in hospital stay when compared with traditional surgical palliation. Pancreaticoduodenectomy with postoperative chemotherapy and radiation therapy is associated with improved long-term survival when compared with patients treated with surgical bypass. These data support the role of palliative pancreaticoduodenectomy in patients with pancreatic carcinoma and with local residual disease.

AB - Objective: The authors define the role of palliative pancreaticoduodenectomy in patients with pancreatic carcinoma. Background: Decreases in perioperative morbidity and modality and improved long term survival associated with pancreaticoduodenectomy for patients with pancreatic carcinoma have clearly established a role for this operation when performed with curative intent. However, most surgeons remain hesitant to perform pancreaticoduodenectomy unless surgical margins are widely clear, choosing rather to perform palliative biliary and gastric bypass. Methods: A single- institution retrospective review was performed comparing the outcome of 64 consecutive patients undergoing pancreaticoduodenectomy for pancreatic carcinoma with gross or microscopic evidence of adenocarcinoma at the surgical resection margins, and 62 consecutive patients found to be unresectable at the time of laparotomy because of local invasion without evidence of metastatic disease (stage III). Combined biliary and gastric bypass were performed in 87% of patients not resected. Results: The two groups were similar with respect to age, gender, race, and presenting symptoms. The hospital modality rate was identical in both groups (1.6%). Fifty-eight percent of patients undergoing pancreaticoduodenectomy had an uncomplicated postoperative course compared with 68% of patients undergoing palliative bypass (not significant). The length of postoperative hospital stay after pancreaticoduodenectomy was 18.4 days, which was significantly longer (p <005) than for patients undergoing palliative bypass (150 days). The overall actuarial survival (Kaplan-Meier) was improved significantly in patients undergoing pancreaticoduodenectomy (p <0.02). Postoperative chemotherapy and radiation therapy improved survival in both groups. Conclusions: Pancreaticoduodenectomy can be performed with a similar perioperative morbidity and modality and only a minimal increase in hospital stay when compared with traditional surgical palliation. Pancreaticoduodenectomy with postoperative chemotherapy and radiation therapy is associated with improved long-term survival when compared with patients treated with surgical bypass. These data support the role of palliative pancreaticoduodenectomy in patients with pancreatic carcinoma and with local residual disease.

UR - http://www.scopus.com/inward/record.url?scp=0029920227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029920227&partnerID=8YFLogxK

U2 - 10.1097/00000658-199606000-00010

DO - 10.1097/00000658-199606000-00010

M3 - Article

VL - 223

SP - 718

EP - 728

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -